About | Free Trial

Last Update

2015-12-02T00:00:00.000Z

This profile was last updated on . .

Is this you? Claim your profile.

Wrong Brian Issell?

Dr. Brian Issell F.

Head of the Clinical and Translational Research Program

University of Hawaii

Direct Phone: (808) ***-****       

Email: b***@***.edu

University of Hawaii

200 W. Kawili St.

Hilo, Hawaii 96720

United States

Company Description

The University of Hawaii at Manoa serves approximately 20,000 students pursuing 225 different degrees. Coming from every Hawaiian island, every state in the nation, and more than 100 countries, UH Manoa students matriculate in an enriching environment for... more

Find other employees at this company (15,476)

Background Information

Education

MD

Web References (194 Total References)


Hospital Management RSS News

www.medworm.com [cached]

Dr. Brian Issell, head of the University of Hawaii's Clinical and Translational Research program, said that he has always encouraged patients to use the Internet as an educational arm… (Source: bizjournals.com Health Care:Hospitals headlines)


About Us | Scripps Translational Science Institute

www.stsiweb.org [cached]

Brian Issell, MD

STSI Director of Clinical Research; SH, Medical Director of Academic Affairs
...
Brian Issell, MD, Vice-President of Scripps Health for Clinical Research, is the STSI Director of Clinical Research. He is exceptionally well qualified for his role on this CTSA proposal. A clinical and translational investigator, administrator and practicing medical oncologist for over 29 years, he led the preclinical to clinical transition of several notable anticancer drugs in the U.S. including cisplatin, carboplatin and etoposide, while working at Bristol Myers (now Bristol Myers Squibb) from 1978-1983, and he then led the initial generation of monoclonal antibody products and the preclinical and clinical development of both monoclonal antibody products and cytokines (including IL-2) while working at Cetus Corporation (now Novartis) from 1983-1988. In 1988 Dr. Issell was recruited to be director of the University of Hawaii's Cancer Research Center. In this role he led the development of new programs in natural products drug discovery, prevention and control and clinical science and the acquisition of first an NCI P20 Cancer Center Planning Grant and then a P30 Cancer Center Support (Core) Grant. He has been PI on multiple clinical research projects (including Phase I studies) funded by R01, R21, U01 and U10 mechanisms. Especially relevant to this application is Dr. Issell's previous role as Program Director of a K12 award for training clinical investigators and his participation in T32 and R25 training awards held by the Cancer Center. In December 2006, Dr. Issell was appointed Corporate Vice President of Clinical Research at Scripps Health. His charge in this role is to lead the expansion of clinical research throughout Scripps Health multi-hospital system and to take it to a new level of excellence through intra- and inter-institutional collaborations and the training and support of outstanding clinical investigators.


About Us | Scripps Translational Science Institute

www.stsiweb.org [cached]

Brian Issell, MD

STSI Director of Clinical Research; SH, Medical Director of Academic Affairs
...
Brian Issell, MD, Vice-President of Scripps Health for Clinical Research, is the STSI Director of Clinical Research. He is exceptionally well qualified for his role on this CTSA proposal. A clinical and translational investigator, administrator and practicing medical oncologist for over 29 years, he led the preclinical to clinical transition of several notable anticancer drugs in the U.S. including cisplatin, carboplatin and etoposide, while working at Bristol Myers (now Bristol Myers Squibb) from 1978-1983, and he then led the initial generation of monoclonal antibody products and the preclinical and clinical development of both monoclonal antibody products and cytokines (including IL-2) while working at Cetus Corporation (now Novartis) from 1983-1988. In 1988 Dr. Issell was recruited to be director of the University of Hawaii's Cancer Research Center. In this role he led the development of new programs in natural products drug discovery, prevention and control and clinical science and the acquisition of first an NCI P20 Cancer Center Planning Grant and then a P30 Cancer Center Support (Core) Grant. He has been PI on multiple clinical research projects (including Phase I studies) funded by R01, R21, U01 and U10 mechanisms. Especially relevant to this application is Dr. Issell's previous role as Program Director of a K12 award for training clinical investigators and his participation in T32 and R25 training awards held by the Cancer Center. In December 2006, Dr. Issell was appointed Corporate Vice President of Clinical Research at Scripps Health. His charge in this role is to lead the expansion of clinical research throughout Scripps Health multi-hospital system and to take it to a new level of excellence through intra- and inter-institutional collaborations and the training and support of outstanding clinical investigators.


About Us | Scripps Translational Science Institute

www.stsiweb.org [cached]

Brian Issell, MD

STSI Director of Clinical Research; SH, Medical Director of Academic Affairs
...
Brian Issell, MD, Vice-President of Scripps Health for Clinical Research, is the STSI Director of Clinical Research. He is exceptionally well qualified for his role on this CTSA proposal. A clinical and translational investigator, administrator and practicing medical oncologist for over 29 years, he led the preclinical to clinical transition of several notable anticancer drugs in the U.S. including cisplatin, carboplatin and etoposide, while working at Bristol Myers (now Bristol Myers Squibb) from 1978-1983, and he then led the initial generation of monoclonal antibody products and the preclinical and clinical development of both monoclonal antibody products and cytokines (including IL-2) while working at Cetus Corporation (now Novartis) from 1983-1988. In 1988 Dr. Issell was recruited to be director of the University of Hawaii's Cancer Research Center. In this role he led the development of new programs in natural products drug discovery, prevention and control and clinical science and the acquisition of first an NCI P20 Cancer Center Planning Grant and then a P30 Cancer Center Support (Core) Grant. He has been PI on multiple clinical research projects (including Phase I studies) funded by R01, R21, U01 and U10 mechanisms. Especially relevant to this application is Dr. Issell's previous role as Program Director of a K12 award for training clinical investigators and his participation in T32 and R25 training awards held by the Cancer Center. In December 2006, Dr. Issell was appointed Corporate Vice President of Clinical Research at Scripps Health. His charge in this role is to lead the expansion of clinical research throughout Scripps Health multi-hospital system and to take it to a new level of excellence through intra- and inter-institutional collaborations and the training and support of outstanding clinical investigators.


About Us | Scripps Translational Science Institute

www.stsiweb.org [cached]

Brian Issell, MD

STSI Director of Clinical Research
...
Brian Issell, MD Brian Issell, MD, Co-Program Director, Vice-President of Scripps Health for Clinical Research, is the STSI Director of Clinical Research. He is exceptionally well qualified for his role on this CTSA proposal. A clinical and translational investigator, administrator and practicing medical oncologist for over 29 years, he led the preclinical to clinical transition of several notable anticancer drugs in the U.S. including cisplatin, carboplatin and etoposide, while working at Bristol Myers (now Bristol Myers Squibb) from 1978-1983, and he then led the initial generation of monoclonal antibody products and the preclinical and clinical development of both monoclonal antibody products and cytokines (including IL-2) while working at Cetus Corporation (now Novartis) from 1983-1988. In 1988 Dr. Issell was recruited to be director of the University of Hawaii's Cancer Research Center. In this role he led the development of new programs in natural products drug discovery, prevention and control and clinical science and the acquisition of first an NCI P20 Cancer Center Planning Grant and then a P30 Cancer Center Support (Core) Grant. He has been PI on multiple clinical research projects (including Phase I studies) funded by R01, R21, U01 and U10 mechanisms. Especially relevant to this application is Dr. Issell's previous role as Program Director of a K12 award for training clinical investigators and his participation in T32 and R25 training awards held by the Cancer Center. In December 2006, Dr. Issell was appointed Corporate Vice President of Clinical Research at Scripps Health. His charge in this role is to lead the expansion of clinical research throughout Scripps Health multi-hospital system and to take it to a new level of excellence through intra- and inter-institutional collaborations and the training and support of outstanding clinical investigators.

Similar Profiles

Other People with this Name

Other people with the name Issell

George Issell
The Windsor Transportation Club Inc

Hagen Issell
NZTC Pasifika

Natasha Issell
ARC Plastic Surgery

Sheila Issell
Auslan Connections

Danica Issell
28 Too Many

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory